The WACC of Marinomed Biotech AG (MARI.VI) is 5.3%.
| Range | Selected | |
| Cost of equity | 5.00% - 13.00% | 9.00% |
| Tax rate | 0.10% - 0.30% | 0.20% |
| Cost of debt | 4.00% - 4.50% | 4.25% |
| WACC | 4.2% - 6.4% | 5.3% |
| Category | Low | High |
| Long-term bond rate | 2.8% | 3.3% |
| Equity market risk premium | 5.7% | 6.7% |
| Adjusted beta | 0.39 | 1.38 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.00% | 13.00% |
| Tax rate | 0.10% | 0.30% |
| Debt/Equity ratio | 3.53 | 3.53 |
| Cost of debt | 4.00% | 4.50% |
| After-tax WACC | 4.2% | 6.4% |
| Selected WACC | 5.3% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for MARI.VI:
cost_of_equity (9.00%) = risk_free_rate (3.05%) + equity_risk_premium (6.20%) * adjusted_beta (0.39) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.